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EFFICACY OF IMMUNIZATION AGAINST HEPATITIS B VIRUS INFECTION
IN ACUTE LYMPHOBLASTIC LEUKEMIA
V.R. Prasanth, Binitha Rajeswari, T. Priyakumary, Parukuttyamma
Kusumakumary. Division of Pediatric Oncology, Regional Cancer Centre,
Thiruvananthapuram, India
Introduction: Children with malignant disease are at an especially high
risk for developing hepatitis B virus infection from immunosuppression
secondary to chemotherapy, radiotherapy andmultiple blood transfusions.
Most of the children infected with HBV develop chronic hepatitis. The
increasing potential for the cure of childhood malignant diseases em-
phasizes the need for a method of reducing hepatitis and its sequelae in
these children.
Objective: The aim of the study was to assess whether immunization
against Hepatitis B (Hepatitis B vaccination +/- Hepatitis B Immunoglob-
ulin) prior to start of chemotherapy provides protective anti HBs titer in
patients with Acute Lymphoblastic Leukemia.
Materials and Methods: This observational study included 104 consecu-
tive children with Acute Lymphoblastic Leukemia treated in Paediatric
Oncology Division, Regional Cancer Centre, Thiruvanathapuram and on
follow up after completion of chemotherapy.The minimum duration of
follow up for inclusion in study was 6 months.The details regarding anti
HBs titers at diagnosis and immunization given were obtained from the
case records.Based on the intial anti HBs titers childrenwere divided into 2
groups, those with protective anti HBs titers (> 10IU/L) and those with
non-protective titers (< 10IU/L).As per the divisions policy, all children
with protective anti HBs titers had received single booster of double dose
of Hepatitis B vaccine.Those with non-protective anti Hbs titers received
HBIG (20IU/Kg ;Max 400IU) followed by double dose of Hepatitis B vaccine
at 0,1,6 months starting 2 months after HBIG. AntiHBsAg titers were done
at follow up using Enzyme Linked Fluoroscent Assay method using VIDAS
(Bio-Merieux).
Results: Of the 104 children included in the study, 67 (64.4%) children had
protective anti HBs titers at presentation, whereas 37 (35.6%) had non-
protective titers. At follow up, 29 (27.8%) children had protective anti HBs
titers and 75 (72.2%) children had non-protective titers (<10 IU/L).Of the 67
children with protective antiHBstitres, 40.2% (n¼27) retained their pro-
tective titers, whereas 59.8% (n¼40) lost their protective titers.In the 37
children with non eprotective antiHBs titers at presentation only 5.4%
(n¼2) developed protective titers following passive and active immuni-
zation, whereas 96.4 % (n¼35) failed to seroconvert.
Discussion: Children receiving chemotherapy even with protective
antiHBs titers at presentation show a loss of protective titers, inspite of
receiving a single booster of double dose HBV vaccine.Those with non-
protective titers, failed to seroconvert despite a combination of passive and
active immunization .The loss of antiHBs titers occurred irrespective of the
levels of initial anti HBs titers larger sample size is required to statistically
validate these results
Conclusion: The loss of protective titers and the failure to seroconvert in
Acute Lymphoblastic Leukemia children receiving chemotherapy is a
concern especially in resource limited settings.The immunization as per this
schedule does not seem to offer protective titres against HBV.There is
probably a need formore frequentmonitoring of antiHBs titers and repeated
administration of Hepatitis B Immunoglobulin as passive prophylaxis which
in developing countries like ours is limited by ﬁnancial constraints.
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VORICONAZOLE PLASMA LEVELS, ITS DETERMINANTS, AND IMPACT ON
OUTCOME OF INVASIVE FUNGAL INFECTIONS IN CHILDREN WITH
CANCER: A PROSPECTIVE STUDY
Vasudeva Bhat, Shripad Banavali, Girish Chinnaswamy, Gaurav
Narula, Tushar Vora, Maya Prasad, Nikita Shah, Brijesh Arora. Tata
Memorial Hospital, Mumbai, IndiaBackground: We evaluated voriconazole plasma levels and determined
the impact of age, dose, route, generic formulations, and concomitant
drugs on plasma levels as well as impact of levels on outcome of invasive
fungal infections (IFI).
Methods: We prospectively studied 256 consecutive children (<19 years)
given voriconazole either for prophylaxis (N-154) or treatment (N-102) of
IFI between August 2008 and February 2016 as per the recommended
doses. IFI diagnosis and clinical outcome evaluation were based on EORTC
Mycoses Study Group (‘EORTC/MSG’) deﬁnitions. The therapeutic range
was deﬁned as 1e5 mg/ml.
Results: A total of 458 voriconazole trough measurements (median age 8
years) were analysed at steady-state [75 on intravenous (IV) and 181 on
oral (PO) doses]. Signiﬁcant Inter- and intrapatient variability in levels was
observed and 46% of patients required dose adjustment. The median vor-
iconazole dose was 16 mg/kg/day and the median duration of therapy was
6 weeks. 53% of children starting with the recommended dose achieved an
adequate trough level and 61% after therapeutic drug monitoring (TDM)-
based dose adjustments. A signiﬁcant correlation between oral doses and
trough levels of voriconazole was observed in patients less than 11 years
old (Spearman's rank correlation coefﬁcient ¼0.18, P < 0.03). A signiﬁcant
relationship was established between plasma levels above normal range
and liver toxicity (P¼0.03). On IV to oral switch, 25% children had drop in
the serum levels to subtherapeutic levels. No impact of gender, steroids
usage, and use of generic formulation was observed on levels or outcome.
Children with Voriconazole level <1 mg /ml were more likely to have
treatment failure at week 6 of voriconazole therapy compared to children
with >1mg/ml (failure, 20.4% vs. 2.1%; P <0.001).). 26% children with sub-
optimal trough levels at 12 hours post voriconazole showed optimal levels
at 8 hours suggesting early plasma clearance and need for frequent dosing.
Conclusions: Our study conﬁrms the large Inter- and intrapatient vari-
ability in voriconazole trough plasma levels particularly after enteral
dosing necessitating higher than recommended doses in young children,
and a trend to non-linear pharmacokinetics in older patients. A signiﬁcant
relationship between voriconazole trough >1 mg/mL and outcomes as well
as some adverse events was conﬁrmed justifying the TDM especially in
young children.
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REGULAR NUTRITIONAL ASSESSMENT OF CHILDREN WITH
MALIGNANCY: OBSERVATIONS OF A NUTRITIONIST DEDICATED TO A
PAEDIATRIC ONCOLOGY UNIT
Syed Anis Fathima, Nutritionist 1, Tarangini Durugappa 2, Anand
Prakash 2. 1Cuddles Foundation, India; 2Department of Paediatrics, Unit of
Hematology e Oncology, St John's Medical College Hospital, Bangalore, India
Abstract
Introduction: Nutritional status is recognised to be amodiﬁable risk factor
for treatment outcomes in Pediatric Oncology. In a developing country
Non- Governmental Organizations can play an important role in sup-
portive care. A Nutritionist supported by Cuddles foundation started
nutritional assessment and intervention at our centre from March 2016.
Objective: To determine the nutritional status in childrenwithmalignancy
at the start of therapy and on serial follow up by a nutritionist dedicated to
the Paediatric Oncology Unit.
Method: All children diagnosed with malignancy between March 2016
and August 2016 were included. Demographic details of children were
collected. Anthropometric indices (Weight, Height, BMI and Mid Upper
Arm Circumference) were recorded at serial time points (at diagnosis and
at follow up visits of 6 to 8 weeks). Counselling of appropriate diet and
enteral based formula feeding were the nutritional interventions. Changes
in nutritional status during this period were analysed.
Results: A total of 27 children were analysed including 15 Haemato-
lymphoid and 12 solid tumors. Mean age of children was 5.6yrs (9 months
to 16 yrs) of which 19 were males and 8 were females. Based on BMI,
21(77.5%) children started therapy with under nutrition including Mild
(-1to -2SD), Moderate (-2 to -3 SD), Severe (<-3SD)malnutrition in 7 (26%),
7 (26%) and 8 (30%) respectively. Two (7.5%) children were overweight at
the start of therapy. On follow up, 46% of children had improvement, 26.9%
were static and 26.9% had a worsening in nutritional status during their
follow up visits. Of 8 (29.6%) children who started with severe
